乳腺癌HER-2基因检测的临床价值  

Detection of HER-2 oncogene and the clinical significance in breast cancer

作　　者：刘秋雨[1] 孔令非[1] 刘正国[1] 

机构地区：[1]河南省人民医院病理科,郑州市450003

出　　处：《中华实用诊断与治疗杂志》2010年第8期778-780,共3页Journal of Chinese Practical Diagnosis and Therapy

摘　　要：目的：探讨乳腺癌HER-2基因在蛋白及基因水平的表达情况及其临床应用价值。方法：应用免疫组织化学法及荧光原位杂交法分别测定44例乳腺癌患者HER-2蛋白表达及基因扩增情况。结果：免疫组织化学检测HER-2蛋白,44例乳腺癌中（＋＋＋）11例（25%）,（＋＋）19例（43%）,（＋-0）14例（32%）。荧光原位杂交检测HER-2基因,44例乳腺癌中（＋）10例（23%）,（—）34例（77%）。免疫组织化学检测（＋＋＋）,（＋＋）,（＋-0）与荧光原位杂交检测符合率分别为64%（7/11）,16%（3/16）,100%（14/14）,3组间差异有统计学意义（P〈0.05）。结论：免疫组织化学可作为乳腺癌HER-2是否过表达的初筛,但只有与荧光原位杂交检测方法结合,才能更准确客观地指导临床用药及预后判断。Objective To study the expressions of HER-2 in the protein and gene level in breast cancer and their clinical application.Methods HER-2 protein expression and gene amplification in 44 cases of breast cancer were detected with immunohistochemistry and fluorescence in situ hybridization respectively.Results Of these 44 cases,the expression of HER-2 protein was 3＋ in 11 cases（25%）,2＋ in 19 cases（43%） and 1＋ to 0 in 14 cases（32%）.The amplification of HER-2 gene was positive in 10 cases（23%）,and negative in 34 cases（77%）.The coincidence of fluorescence in situ hybridization was 64%,16% and 100% respectively.The significant difference was found among three groups（P0.05）.Conclusion The immunohistochemistry technique can be used in the initial screening of HER-2 gene overexpression in breast cancer.Only when it is combined with fluorescence in situ hybridization,it could be more accurate and objective for guiding clinical medication and judging the prognosis.

关 键 词：乳腺肿瘤 HER-2基因 免疫组织化学 荧光原位杂交 

分 类 号：R737.9[医药卫生—肿瘤]